Cheaper anti-stroke drug in the offing

Also See:–¬†Urban poor income in AP too low

VIJAYAWADA: In a landmark development, a drug that is expected to drastically bring down the stroke treatment cost, has successfully cleared the trial stage and is all set to enter the market. The drug trials carried out on about 75 stroke patients across the country has been found satisfactory by the Drug Control General of India (DCGI).

According to information, a Pune-based pharmaceutical firm, Genova biopharmaceuticals conducted the trials at different hospitals with prior permission from the drug control authority. The trial named TNKTPA (tenecteplase) was carried out on select patients to test the efficacy of the drug. Interestingly, nine of the total 75 patients picked up for trials, underwent the treatment at the centre of excellence for neurosciences at Aster Rameshhospitals in the city. “We have thrombosed the highest number of patients – nine in one hospital centre during the trial stage of the drug and found it to be extremely wonderful,” Dr Chekuri Murali, the member of the neurologists’ team at Aster Ramesh hospitals, told TOI.

He said that the single dose of the existing drugs used to normalize the physical condition of a stroke patient costs around Rs 66,000 while the latest drug is expected to cost just Rs 28,000. He said that tenecteplase helps defuse the blood clot in the brain and give a lease of life to the victims.
This could revolutionize the treatment of stroke patients in the country as the majority of the victims are keeping away from the hospital for fear of high costs involved in the treatment,” observed chief of Aster Ramesh hospitals group, Dr Ramesh Babu.

Do you like this post?
  • Fascinated
  • Happy
  • Sad
  • Angry
  • Bored
  • Afraid



Please enter your comment!
Please enter your name here